The page is the record's research on the issuer — no analyst, no rating, no view. # Aprea Therapeutics, Inc. (NASDAQ: APRE) — research page As of 2026-11-08 · us-cm-kg · record version 1 ## Identity and listing The issuer is Aprea Therapeutics, Inc., listed on NASDAQ under the ticker APRE, with ISIN US03836J2015. The LEI is not on the record, as no GLEIF record carries the exact legal name in jurisdiction US-DE. The security type is Corporate, the segment is not on the record, the sector is 2834 Pharmaceutical Preparations, and the jurisdiction is United States, Delaware. The issuer is listed and not halted. ## The disclosure read The record holds 71 filings in the window 2025-11-08 to 2026-11-08, across 37 filing days. The median gap between filing days is 5.0 days. The latest filing is dated 2026-11-04, is of type results, and falls 4 days before the record date of 2026-11-08. The exchange median cadence gap is 6.0 days across 4,359 NASDAQ issuers, with a median of 52 filings and a median latency of 5.0 days. The sector median cadence gap is 6.0 days across 526 issuers in 2834 Pharmaceutical Preparations, with a median of 63.0 filings and a median latency of 4.0 days. By type, the window holds 4 agm_egm, 7 corporate_news, 17 directors_dealings, 2 halt_suspension, 8 prospectus, 23 regulatory_filing and 10 results filings. ## Auditor The auditor of record is EisnerAmper LLP, located in Philadelphia, Pennsylvania. The record holds no auditor changes. ## Events and halts The record holds no listing, delisting, or name change lines. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The issuer is listed and not halted. ## Orderability The outcome is not determinable, because the chapter's orderability section carries no client categories and so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04. ## Coverage No research houses were found on the issuer's investor-relations pages. ## Open research No openly published research notes were found on the record. ## Licensed Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded. ## As-of depth The issuer's years sealed are 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12. ## Sources 8 source pages are named on this page; every value above carries its own source page and read date in the numbers. - https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange) - https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin) - https://data.sec.gov/submissions/CIK0001781983.json (identity.jurisdiction) - https://mcp.us-cm-kg.ai/events/NASDAQ/APRE (the disclosure lines) - https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag) - https://www.sec.gov/Archives/edgar/data/1781983/000110465926028068/apre-20251231x10k.htm (the auditor) - https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter) - https://mcp.us-cm-kg.ai/record/NASDAQ/APRE (the record) --- Allooloo Technologies Corp. · https://getresearch.ai/us/NASDAQ/APRE · public-record only · the same page signed and receipted: get_research at https://mcp.getresearch.ai/mcp